Summary NanoCarrier Co Ltd (NanoCarrier) is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology.The company’s pipeline products include NC-6004, NC-4016, NC-6300, VB-111, NC-6201 and NK105.
It offers siRNA micelle, protein micelle, DACH-platin micelle, paclitaxel micelle, pH-sensitive micelle, sensor linked micelle and docetaxel micelle.NanoCarrier’s NC-6004 is used for the treatment for pancreatic cancer, head and neck cancer, bladder cancer, and biliary tract cancer.
The company’s VB-111 is used for the treatment of recurrent glioblastoma, ovarian cancer and thyroid cancer.Its micellar nanoparticle technology is also used in developing cosmetics and healthcare products.
The company operates its office in Tokyo, Japan. NanoCarrier is headquartered in Kashiwa, Japan.
NanoCarrier Co Ltd (4571) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The global macular degeneration treatment market was valued at USD 7,755 million in 2020, and it is expected to reach USD 11,492 million by 2026, registering a CAGR of 6.9% during the period of 2021-2026. The COVID-19 pandemic had a potential economic impact and implications on most of the sectors, including the pharmaceutical and biotech...
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 22.214.171.124) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 126.96.36.199) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 188.8.131.52) - Drugs in Development, 2021 Summary According to the recently published report ’SerineThreonine Protein Kinase Pim 2 - Drugs in Development, 2021’; Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto...
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 184.108.40.206) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 220.127.116.11) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed...
The manufacturing execution system market is expected to grow from USD 11.5 billion in 2021 to USD 17.1 billion by 2026 at a CAGR of 8.3% from 2021 to 2026. A few key factors driving the growth of this market include increasing use of industrial automation in process and discrete industries, increasing IT and OT convergence, and the need for...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market’s maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs,...
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 18.104.22.168) - Drugs in Development, 2021 Summary Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 22.214.171.124) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor...
Left Ventricular Dysfunction (Cardiovascular) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Drugs in Development, 2021, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape. Left...
Hepatic Encephalopathy (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Drugs in Development, 2021, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.